The White House is currently reviewing a federal plan for marijuana and CBD research.

The Food and Drug Administration submitted draft guidance on the issue last week to the White House Office of Management and Budget.

Details about the document — titled “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research” — are sparse. But an FDA spokesperson indicated to Marijuana Moment that it’s related to the agency’s ongoing work to develop broader CBD regulations that could eventually allow for the marketing of cannabis products as dietary supplements or food items.

“We recognize that there is substantial public interest in marketing and accessing CBD for a variety of products. We are working toward a goal of providing additional guidance, and have made substantial progress,” the FDA said in a statement. “There are many questions to explore regarding the science, safety, effectiveness and quality of products containing CBD, and we need to do our due diligence.”